Nachrichten zur Bristol-Myers Squibb Co. Aktie

Bristol Myers Squibb: Aktie bricht nach Zahlen massiv ein – jetzt günstig einsteigen?

Der amerikanische Pharma-Konzern Bristol Myers Squibb hat mit seinen Zahlen zum ersten Quartal für Ernüchterung gesorgt. Nach der Bekanntgabe der…

Bristol Myers Squibb: Aktie bricht nach Zahlen massiv ein – jetzt günstig einsteigen?

Der amerikanische Pharma-Konzern Bristol Myers Squibb hat mit seinen Zahlen zum ersten Quartal für Ernüchterung gesorgt. Nach der Bekanntgabe der…

The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals

Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.…

Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions

…

Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript

BMY earnings call for the period ending March 31, 2024.…

Is Bristol Myers Squibb Stock a Millionaire Maker?

Bristol Myers Squibb faces some challenges, but there could be light at the end of the tunnel for long-term investors.…

Merck jumps on profit beat as Bristol Myers Squibb slips to a loss

Merck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after its cancer drug Keytruda…

Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss

Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.…

Bristol-Myers Squibb stock slips despite earnings beat By Investing.com

Bristol-Myers Squibb stock slips despite earnings beat…

Bristol-Myers Squibb earnings beat by $0.07, revenue topped estimates By Investing.com

Bristol-Myers Squibb earnings beat by $0.07, revenue topped estimates…

Bristol Myers posts quarterly loss, revenue rises 5%

Bristol Myers Squibb on Thursday reported a first-quarter loss as charges related to its recent acquisitions of Karuna Therapeutics, RayzeBio…

Pharmabranche: Neuer Novartis-Chef kommt von Bristol Myers Squibb

Jörg Reinhardt tritt nach zwölf Jahren als Novartis-Chef zurück. Sein Nachfolger steht bereits fest. Er kommt von einem direkten Konkurrenten.…

Anthos Therapeutics Announces Appointment of Bill Meury as CEO

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative…

Is Bristol Myers Squibb A Buy At These Bottom Levels?

…

Bristol Myers Squibb and Cellares reach $380 million supply deal for CAR-T therapies By Reuters

Bristol Myers Squibb and Cellares reach $380 million supply deal for CAR-T therapies…

Got $500? 3 Healthcare Stocks to Buy and Hold Forever

Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.…

Got $500? 3 Healthcare Stocks to Buy and Hold Forever @themotleyfool #stocks $ISRG $BMY $NVO

Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.…

Global CAR T-Cell Therapy Market Size To Worth USD 21.92 Billion By 2033 | CAGR of 17.72%

The Global CAR T-Cell Therapy Market Size was Valued at USD 4.29 Billion in 2023 and the Worldwide CAR T-Cell…

Biotech im Visier - Bristol-Myers Squibb, Formycon, MorphoSys, Vidac Pharma Aktie

Für viele Pharma- und Biotechaktionäre hat dieser Sektor einen ganz besonderen Charme. In dieser hochspekulativen Branche liegen Erfolg und Misserfolg…

Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?

Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard…

Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF? @themotleyfool #stocks $BMY $LLY $^GSPC $NVO $VOO

Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard…

Global Chemotherapy Market Size To Exceed USD 16.2 Billion By 2033 | CAGR of 6.54%

The Global Chemotherapy Market Size was Valued at USD 8.6 Billion in 2023 and the Worldwide Chemotherapy Market Size is…

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

…

Übernahmewelle rollt: Jetzt drei weitere heiße Kandidaten kennenlernen

87 Prozent, 97 Prozent und 105 Prozent – diese Aufschläge haben die großen Pharma-Firmen Eli Lilly, Astrazeneca und Bristol Myers…

Übernahmewelle rollt: Jetzt drei weitere heiße Kandidaten kennenlernen

87 Prozent, 97 Prozent und 105 Prozent - diese Aufschläge haben die großen Pharma-Firmen Eli Lilly, Astrazeneca und Bristol Myers…

Übernahmewelle rollt: Jetzt drei weitere heiße Kandidaten kennenlernen

87 Prozent, 97 Prozent und 105 Prozent – diese Aufschläge haben die großen Pharma-Firmen Eli Lilly, Astrazeneca und Bristol Myers…

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Bristol Myers Squibb: The Comeback Is Unfolding

…

Is Bristol Myers Squibb Stock a Buy?

The company is going through a rough patch.…

[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Bristol-Myers Squibb Is Not A Buy For Me

…

Bristol Myers Squibb completes Karuna Therapeutics buyout By Investing.com

Bristol Myers Squibb completes Karuna Therapeutics buyout…

Bristol-Myers Squibb Company (BMY) Barclays 26th Annual Global Healthcare Conference (Transcript)

…

Karuna Therapeutics set to merge with Bristol-Myers Squibb By Investing.com

Karuna Therapeutics set to merge with Bristol-Myers Squibb…

Bristol-Myers Squibb: Großes Interesse an ADC-Playern - Tubulis holt hochkarätige Investoren an Bord - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Bristol-Myers Squibb Company…